Akari Therapeutics Plc — Director's Dealing 2015

Jan 12, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celsus Therapeutics Plc. (CLTX)
CIK: 0001541157
Period of Report: 2015-01-08

Reporting Person: Cohen Mark S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-01-08	Ordinary Shares	X	50700	$0.0167	Acquired	50700	Direct
2015-01-08	Ordinary Shares	X	152000	$0.0153	Acquired	152000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-08	Options to Purchase Ordinary Shares	$0.0167	X	50700	Disposed	2015-01-18	Ordinary Shares (50700)	Indirect
2015-01-08	Options to Purchase Ordinary Shares	$0.0153	X	152000	Disposed	2017-03-12	Ordinary Shares (152000)	Indirect

Footnotes

F1: The exercise price for these options to purchase ordinary shares is 0.01 pound sterling.